August 22, 2017 1:31 PM ET

Pharmaceuticals

Company Overview of Ansun Biopharma, Inc.

Company Overview

Ansun Biopharma, Inc. manufactures and commercializes biopharmaceuticals to prevent and treat life-threatening human diseases. Its products include Fludase, a drug candidate for the prophylaxis and treatment of respiratory infections caused by various types of influenza virus, including the types of virus that may cause a potential influenza pandemic, as well as various types of parainfluenza virus. The company’s products also include Viradin, an intravenous therapeutic for sepsis and septic shock, as well as viral hemorrhagic fever caused by such pathogens as Ebola and Marburg viruses. In addition, its products include TOSAP, a formulation technology capable of creating microspheres and nan...

10665 Sorrento Valley Road

Suite 105

San Diego, CA 92121

United States

Founded in 2002

Phone:

858-452-2631

Fax:

858-452-2534

Key Executives for Ansun Biopharma, Inc.

Co-Founder and President of Research & Development
Assistant Vice President of Finance & Administration
Executive Vice President of Clinical Development & Medical Affairs
Age: 56
Vice President of Corporate Development
Compensation as of Fiscal Year 2017.

Ansun Biopharma, Inc. Key Developments

Ansun Biopharma, Inc. Presents at Aegis Capital Corp. 2016 Growth Conference, Sep-21-2016 04:30 PM

Ansun Biopharma, Inc. Presents at Aegis Capital Corp. 2016 Growth Conference, Sep-21-2016 04:30 PM. Venue: The Encore at Wynn Las Vegas, 3131 Las Vegas Blvd, Las Vegas, NV 89109, United States.

Ansun Biopharma, Inc. Presents at 2016 BIO International Convention, Jun-08-2016 10:45 AM

Ansun Biopharma, Inc. Presents at 2016 BIO International Convention, Jun-08-2016 10:45 AM. Venue: Moscone Center, San Francisco, California, United States.

Ansun BioPharma Announces Potent In-Vitro DAS181 Activity Against Respiratory Syncytial Virus at 5th Congress of Virology

Ansun BioPharma announced preliminary data suggesting in-vitro activity of DAS181 against Respiratory Syncytial Virus (RSV), a virus which causes significant morbidity and mortality in patients. The data was presented at the 5th Congress of Virology in Atlanta, Georgia in a keynote address by Ronald Moss, MD, CEO of Ansun. The in-vitro inhibition against the virus was observed to be more potent than Ribavarin, the current treatment for RSV.

Similar Private Companies By Industry

Company Name Region
1st Order Pharmaceuticals, Inc. United States
21st Century Animal Health United States
3 Buds' Organics LLC United States
4P Therapeutics LLC United States
60° Pharmaceuticals, LLC United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
\
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
The Advertising Council, Inc. United States
Bertelsmann AG Europe
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Ansun Biopharma, Inc., please visit --. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.